{"id":946455,"date":"2026-03-24T07:45:50","date_gmt":"2026-03-24T11:45:50","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/rezolute-provides-update-on-its-congenital-hyperinsulinism-program-following-fda-meeting\/"},"modified":"2026-03-24T07:45:50","modified_gmt":"2026-03-24T11:45:50","slug":"rezolute-provides-update-on-its-congenital-hyperinsulinism-program-following-fda-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/rezolute-provides-update-on-its-congenital-hyperinsulinism-program-following-fda-meeting\/","title":{"rendered":"Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting"},"content":{"rendered":"<h2>\nFDA encourages the Company to submit comprehensive data from sunRIZE and the ongoing open-label extension to inform next steps for the program<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p>REDWOOD CITY, Calif., March  24, 2026  (GLOBE NEWSWIRE) &#8212; <strong>Rezolute, Inc. (Nasdaq: RZLT) (\u201cRezolute\u201d or the \u201cCompany\u201d),<\/strong>\u00a0a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced\u00a0outcomes\u00a0from an in-person Type B meeting with the U.S. Food and Drug Administration (FDA) held on March 17, 2026, related to\u00a0sunRIZE, a Phase 3, multicenter, double-blind, randomized, placebo-controlled safety and efficacy study of ersodetug for the treatment of congenital HI.\u00a0\u00a0\u00a0<\/p>\n<p>In December 2025, the Company reported that sunRIZE\u00a0demonstrated reductions from baseline in hypoglycemia\u00a0events,\u00a0but\u00a0the study did not meet its primary\u00a0endpoint because\u00a0the reductions\u00a0were not statistically significant compared to placebo, which the Company believes was a result\u00a0of\u00a0a\u00a0pronounced study effect.\u00a0<\/p>\n<p>Although\u00a0consistent\u00a0and clinically significant\u00a0improvements in time in hypoglycemia\u00a0by\u00a0continuous glucose monitoring (CGM)\u00a0were\u00a0observed\u00a0compared to placebo\u00a0over the course of the\u00a0entire\u00a0pivotal\u00a0treatment\u00a0period,\u00a0nominal statistical significance was not achieved in this key secondary endpoint at the pre-specified Week 24 end-of-treatment period.\u00a0\u00a0<\/p>\n<p>During the meeting\u00a0with FDA, the Company presented\u00a0summary results from\u00a0sunRIZE\u00a0including: (i)\u00a0information to support\u00a0the Company\u2019s belief that the primary endpoint was confounded as a result of behavioral factors; (ii)\u00a0evidence of pharmacologic activity,\u00a0as target therapeutic drug concentrations were achieved in both treatment groups with highly sensitive biomarker responses\u00a0of decreased insulin cell signaling; (iii)\u00a0consistent\u00a0improvements\u00a0compared to placebo\u00a0in time in hypoglycemia and a variety of\u00a0other\u00a0CGM-based\u00a0glycemic endpoints; and (iv)\u00a0preliminary\u00a0favorable\u00a0observations from the ongoing open-label extension\u00a0portion of the study (OLE), which indicate\u00a0continued\u00a0improvement in\u00a0glycemic parameters\u00a0in the\u00a0ersodetug\u00a0treatment\u00a0arms and placebo roll-over,\u00a0concurrent with\u00a0a notable reduction of other background\u00a0standard-of-care\u00a0therapies.\u00a0\u00a0\u00a0<\/p>\n<p>FDA\u00a0acknowledged\u00a0the\u00a0challenges\u00a0posed by the potential impact of varied behavioral factors on clinical trials\u00a0in\u00a0this heterogeneous patient population, including the associated limitations of self-monitored blood glucose (SMBG) based metrics in measuring hypoglycemia in congenital HI.\u00a0<\/p>\n<p>The Company believes that the\u00a0unblinded\u00a0nature of self-monitored glucose\u00a0necessary\u00a0for\u00a0patient standard of care, together with perceptions of treatment assignment,\u00a0may have led to\u00a0divergent behaviors between treatment groups during the study, which may have impacted\u00a0the measurement of\u00a0hypoglycemia\u00a0by SMBG.<\/p>\n<p>While acknowledging these challenges, the agency reiterated the expectation for adequate and well-controlled studies and outcomes as the standard for evaluating substantial evidence of efficacy criteria as the basis for approving new therapies.<\/p>\n<p>The agency and the Company then discussed summary outcomes from various CGM-based glycemic endpoints and preliminary observations from the OLE.\u00a0These and other outcomes from the pivotal portion of the sunRIZE trial will be shared by oral presentation at an upcoming scientific conference.<\/p>\n<p>As a next step for the program, FDA encouraged the Company to\u00a0submit\u00a0study reports and analysis\u00a0datasets for the\u00a0agency\u2019s\u00a0independent evaluation.\u00a0Following that review, the Company believes that a determination may be made whether there is sufficient evidence to support the submission of a marketing application for sunRIZE or if additional information is required. The Company expects to have an update on the program in the second half of\u00a02026.\u00a0\u00a0\u00a0<\/p>\n<p>\u201cWe are extremely encouraged by the outcome of our meeting with FDA including the fact that, while acknowledging their feedback was preliminary, the agency did not dismiss sunRIZE outright on the basis of\u00a0not meeting its primary endpoint,\u201d\u00a0said Nevan Charles Elam, Chief Executive Officer and Founder of\u00a0Rezolute.\u00a0\u201cFDA\u00a0was engaged\u00a0with the\u00a0content\u00a0we presented, asked astute\u00a0questions\u00a0necessary to fully understand the\u00a0results, and\u00a0expressed\u00a0a\u00a0desire\u00a0to conduct a thorough review that would assist in\u00a0decision making regarding\u00a0advancement of the program.\u201d<\/p>\n<p>Mr. Elam continued, \u201cWe are grateful for FDA\u2019s hands-on approach and look forward to continuing to work with them to hopefully find a timely path forward to make ersodetug available to patients and families in need.\u201d\u00a0\u00a0\u00a0<\/p>\n<p>\u201cAs an attendee of the meeting, I was extremely impressed observing FDA and Rezolute working together with a common understanding of the\u202fprofound burden\u202fcongenital\u202fhyperinsulinism places on patients and caregivers, and for their commitment to advance meaningful improvements in care,\u201d\u202fsaid\u202fJulie Raskin,\u202fChief Executive Officer\u202fof Congenital Hyperinsulinism International, an international advocacy organization.\u202f\u201cOur community\u202fhas long awaited new treatment options,\u202fand\u202fthis open dialogue reflects important progress toward potentially safely bringing more effective and better-tolerated\u202ftherapies.\u201d\u202f\u00a0\u00a0<\/p>\n<p>\n        <strong>About Ersodetug<\/strong>\u00a0<\/p>\n<p>Ersodetug is a fully human monoclonal antibody that binds allosterically to the insulin receptor to decrease receptor over-activation by insulin and related substances (such as IGF-2) in the setting of hyperinsulinism (HI), thereby improving hypoglycemia. Because ersodetug acts downstream from the pancreas, it has the potential to be universally effective at treating hypoglycemia due to any congenital or\u00a0acquired\u00a0form of HI.\u00a0<\/p>\n<p>\n        <strong>About Rezolute, Inc.<\/strong>\u00a0<\/p>\n<p>Rezolute is a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI). The Company\u2019s antibody therapy, ersodetug, is designed to treat all forms of HI and has been studied in clinical trials and used in real-world cases for the treatment of both congenital and tumor HI. For more information, visit\u202f<a href=\"https:\/\/www.rezolutebio.com\/\" rel=\"nofollow\" target=\"_blank\"><strong>www.rezolutebio.com<\/strong><\/a>.\u00a0<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\u00a0\u00a0<\/p>\n<p>This release, like many written and oral communications presented by Rezolute and our authorized officers, may\u00a0contain\u00a0certain forward-looking statements\u00a0regarding\u00a0our prospective performance and strategies within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of Rezolute, are generally identified by use of words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;strive,&#8221; &#8220;try,&#8221; or future or conditional verbs such as &#8220;could,&#8221; &#8220;may,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; or similar expressions. These forward-looking statements include, but are not limited to, the potential efficacy of ersodetug in treating hypoglycemia, the timing and ability of the Company to provide study reports and analysis datasets for the FDA\u2019s independent evaluation, the persuasiveness of the study reports and analysis datasets and the possibility of FDA agreeing to advance the congenital HI program based on those study reports and analysis datasets notwithstanding the lack of statistical significance in the sunRIZE study, the timing of any FDA response to the study reports and analysis datasets, the timing of any update on the sunRIZE program and the timing and content of any future presentations and market updates related the sunRIZE program. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain.\u00a0Accordingly, actual results may differ materially from\u00a0anticipated\u00a0results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, Rezolute undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made. Important factors that may cause such a difference include any other factors discussed in our filings with the SEC, including the Risk Factors contained in\u00a0Rezolute\u2019s\u00a0Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available at the U.S. Securities and Exchange Commission\u2019s website at www.sec.gov. You are urged to consider these factors carefully\u00a0in\u00a0evaluating the forward-looking statements in this release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement.\u00a0<\/p>\n<p>\n        <strong>Rezolute Contacts:<\/strong>\u00a0<\/p>\n<p>Christen Baglaneas <br \/><a href=\"mailto:cbaglaneas@rezolutebio.com\" rel=\"nofollow\" target=\"_blank\">cbaglaneas@rezolutebio.com<\/a><br \/>508-272-6717\u00a0<\/p>\n<p>Carrie McKim <br \/><a href=\"mailto:cmckim@rezolutebio.com\" rel=\"nofollow\" target=\"_blank\">cmckim@rezolutebio.com<\/a> \u00a0<br \/>336-608-9706\u00a0<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NzM1MCM3NTAwMzI0IzIwOTA4MTQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZjNjY2ZlNjktZjg5NS00ZDU1LWI2M2ItZjZhYjJiMjFjZjFmLTExMDIzODUtMjAyNi0wMy0yNC1lbg==\/tiny\/Rezolute-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>FDA encourages the Company to submit comprehensive data from sunRIZE and the ongoing open-label extension to inform next steps for the program REDWOOD CITY, Calif., March 24, 2026 (GLOBE NEWSWIRE) &#8212; Rezolute, Inc. (Nasdaq: RZLT) (\u201cRezolute\u201d or the \u201cCompany\u201d),\u00a0a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced\u00a0outcomes\u00a0from an in-person Type B meeting with the U.S. Food and Drug Administration (FDA) held on March 17, 2026, related to\u00a0sunRIZE, a Phase 3, multicenter, double-blind, randomized, placebo-controlled safety and efficacy study of ersodetug for the treatment of congenital HI.\u00a0\u00a0\u00a0 In December 2025, the Company reported that sunRIZE\u00a0demonstrated reductions from baseline in hypoglycemia\u00a0events,\u00a0but\u00a0the study did not meet its primary\u00a0endpoint because\u00a0the reductions\u00a0were not statistically significant compared &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/rezolute-provides-update-on-its-congenital-hyperinsulinism-program-following-fda-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-946455","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/rezolute-provides-update-on-its-congenital-hyperinsulinism-program-following-fda-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"FDA encourages the Company to submit comprehensive data from sunRIZE and the ongoing open-label extension to inform next steps for the program REDWOOD CITY, Calif., March 24, 2026 (GLOBE NEWSWIRE) &#8212; Rezolute, Inc. (Nasdaq: RZLT) (\u201cRezolute\u201d or the \u201cCompany\u201d),\u00a0a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced\u00a0outcomes\u00a0from an in-person Type B meeting with the U.S. Food and Drug Administration (FDA) held on March 17, 2026, related to\u00a0sunRIZE, a Phase 3, multicenter, double-blind, randomized, placebo-controlled safety and efficacy study of ersodetug for the treatment of congenital HI.\u00a0\u00a0\u00a0 In December 2025, the Company reported that sunRIZE\u00a0demonstrated reductions from baseline in hypoglycemia\u00a0events,\u00a0but\u00a0the study did not meet its primary\u00a0endpoint because\u00a0the reductions\u00a0were not statistically significant compared &hellip; Continue reading &quot;Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/rezolute-provides-update-on-its-congenital-hyperinsulinism-program-following-fda-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-24T11:45:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NzM1MCM3NTAwMzI0IzIwOTA4MTQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rezolute-provides-update-on-its-congenital-hyperinsulinism-program-following-fda-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rezolute-provides-update-on-its-congenital-hyperinsulinism-program-following-fda-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting\",\"datePublished\":\"2026-03-24T11:45:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rezolute-provides-update-on-its-congenital-hyperinsulinism-program-following-fda-meeting\\\/\"},\"wordCount\":1311,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rezolute-provides-update-on-its-congenital-hyperinsulinism-program-following-fda-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3NzM1MCM3NTAwMzI0IzIwOTA4MTQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rezolute-provides-update-on-its-congenital-hyperinsulinism-program-following-fda-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rezolute-provides-update-on-its-congenital-hyperinsulinism-program-following-fda-meeting\\\/\",\"name\":\"Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rezolute-provides-update-on-its-congenital-hyperinsulinism-program-following-fda-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rezolute-provides-update-on-its-congenital-hyperinsulinism-program-following-fda-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3NzM1MCM3NTAwMzI0IzIwOTA4MTQ=\",\"datePublished\":\"2026-03-24T11:45:50+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rezolute-provides-update-on-its-congenital-hyperinsulinism-program-following-fda-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rezolute-provides-update-on-its-congenital-hyperinsulinism-program-following-fda-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rezolute-provides-update-on-its-congenital-hyperinsulinism-program-following-fda-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3NzM1MCM3NTAwMzI0IzIwOTA4MTQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3NzM1MCM3NTAwMzI0IzIwOTA4MTQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rezolute-provides-update-on-its-congenital-hyperinsulinism-program-following-fda-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/rezolute-provides-update-on-its-congenital-hyperinsulinism-program-following-fda-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting - Market Newsdesk","og_description":"FDA encourages the Company to submit comprehensive data from sunRIZE and the ongoing open-label extension to inform next steps for the program REDWOOD CITY, Calif., March 24, 2026 (GLOBE NEWSWIRE) &#8212; Rezolute, Inc. (Nasdaq: RZLT) (\u201cRezolute\u201d or the \u201cCompany\u201d),\u00a0a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced\u00a0outcomes\u00a0from an in-person Type B meeting with the U.S. Food and Drug Administration (FDA) held on March 17, 2026, related to\u00a0sunRIZE, a Phase 3, multicenter, double-blind, randomized, placebo-controlled safety and efficacy study of ersodetug for the treatment of congenital HI.\u00a0\u00a0\u00a0 In December 2025, the Company reported that sunRIZE\u00a0demonstrated reductions from baseline in hypoglycemia\u00a0events,\u00a0but\u00a0the study did not meet its primary\u00a0endpoint because\u00a0the reductions\u00a0were not statistically significant compared &hellip; Continue reading \"Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/rezolute-provides-update-on-its-congenital-hyperinsulinism-program-following-fda-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-24T11:45:50+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NzM1MCM3NTAwMzI0IzIwOTA4MTQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rezolute-provides-update-on-its-congenital-hyperinsulinism-program-following-fda-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rezolute-provides-update-on-its-congenital-hyperinsulinism-program-following-fda-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting","datePublished":"2026-03-24T11:45:50+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rezolute-provides-update-on-its-congenital-hyperinsulinism-program-following-fda-meeting\/"},"wordCount":1311,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rezolute-provides-update-on-its-congenital-hyperinsulinism-program-following-fda-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NzM1MCM3NTAwMzI0IzIwOTA4MTQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rezolute-provides-update-on-its-congenital-hyperinsulinism-program-following-fda-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/rezolute-provides-update-on-its-congenital-hyperinsulinism-program-following-fda-meeting\/","name":"Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rezolute-provides-update-on-its-congenital-hyperinsulinism-program-following-fda-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rezolute-provides-update-on-its-congenital-hyperinsulinism-program-following-fda-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NzM1MCM3NTAwMzI0IzIwOTA4MTQ=","datePublished":"2026-03-24T11:45:50+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rezolute-provides-update-on-its-congenital-hyperinsulinism-program-following-fda-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/rezolute-provides-update-on-its-congenital-hyperinsulinism-program-following-fda-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rezolute-provides-update-on-its-congenital-hyperinsulinism-program-following-fda-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NzM1MCM3NTAwMzI0IzIwOTA4MTQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NzM1MCM3NTAwMzI0IzIwOTA4MTQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rezolute-provides-update-on-its-congenital-hyperinsulinism-program-following-fda-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/946455","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=946455"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/946455\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=946455"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=946455"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=946455"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}